OMass secured $310 million to advance a drug program for congenital adrenal hyperplasia, targeting an option intended to compete in a market dominated by Neurocrine’s current FDA-approved therapy. The funding also arrives as Vertex Pharmaceuticals is poised to introduce additional competition, underscoring the race for next-generation endocrine treatments.